HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Talc Suit Dismissals: Plaintiffs Lack Causation Thread For Proof Quilt

This article was originally published in The Rose Sheet

Executive Summary

Following two plaintiff victories and hefty damages awards in a Missouri circuit court earlier this year, J&J succeeded last week in having a pair of talc cancer cases dismissed in New Jersey due to plaintiffs’ lack of compelling causation evidence. With more than 1,000 talc suits against J&J still pending, the relative weight of expert testimonies – and venue – likely will continue to be significant factors in how they play out.

You may also be interested in...

Court’s Rejection Of Evidence Countering ‘Willful’ Deception On Talc Ends J&J’s Appeal Streak

Johnson & Johnson failed to convince a Missouri appeals court to overturn a lower court finding that plaintiffs presented clear and convincing evidence the talc in its Johnson’s Baby Powder causes ovarian cancer and that the firm knew and improperly influenced regulators to allow use of the ingredient.

J&J’s Discontinuation Of Johnson’s Baby Powder Linked To April Federal Court Ruling

Legal experts note that J&J’s decision to end Johnson’s Baby Powder sales in the US and Canada closely followed a New Jersey federal court decision that largely denied the firm’s motions to bar testimony from plaintiff experts in multi-district talc litigation comprising around 16,000 cases.

Canadian Authorities Say Some Cosmetic Talc Applications May Endanger Human Health

Health Canada and Canada’s environmental agency issued a draft screening assessment Dec. 8 identifying talc as potentially hazardous to consumers when used in cosmetic powders that may be inhaled or products applied to female genitals. Finalization of the assessment in its current form would trigger risk management actions.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts